• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Finance

Biomica Announces Closing of $20 Million Financing Round

April 27, 2023 Microbiome Times

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it has closed a financing round of $20 million. The round was […]

Editor's Choice

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™

April 27, 2023 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults […]

Editor's Choice

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

April 25, 2023 Microbiome Times

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead […]

Finance

DSM agrees terms to acquire postbiotics pioneer Adare Biome

April 19, 2023 Microbiome Times

Royal DSM, a global science-based leader in health, nutrition and bioscience, announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and […]

Pharma & Human Health

Vedanta Biosciences Publishes Phase 2 Results

April 18, 2023 Microbiome Times

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication of Phase 2 study results from its lead program, VE303, in […]

Finance

Microbiotica Announces Clinical Trial Collaboration with MSD

April 13, 2023 Microbiome Times

Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, […]

Finance

Metagen Therapeutics Raises Over 8M $ in Initial Closing of Series A

April 12, 2023 Microbiome Times

Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has announced a JPY 1.1B investment in its Series A funding as of April, 2023. MGTx has been accelerating […]

Editor's Choice

Researchers create virus-resistant, safely restrained E. coli

April 10, 2023 Microbiome Times

In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified […]

Finance

Aurealis therapeutics raises $10 million in an oversubscribed series A financing

April 3, 2023 Microbiome Times

Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish […]

Pharma & Human Health

Human body a breeding ground for antimicrobial resistance genes

March 31, 2023 Microbiome Times

The community of microbes living in and on our bodies may be acting as a reservoir for antibiotic resistance, according to new research from the Earlham Institute and Quadram Institute in Norwich. The use of […]

Pharma & Human Health

IFF Achieves Industrial Scale Production of a Strict Anaerobic ‘Next Generation’ Probiotic Strain

March 30, 2023 Microbiome Times

IFF—a leading global player in the health and wellbeing industry—today reveals it has achieved the successful production of a strict anaerobic ‘next generation’ probiotic strain at industrial scale. The remarkable milestone demonstrates IFF’s unique capabilities […]

Posts navigation

« 1 2 3 … 65 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
  • DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
    May 10, 2023
  • Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
    April 27, 2023
  • Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    April 25, 2023
  • Researchers create virus-resistant, safely restrained E. coli
    April 10, 2023
sign up

Sign up to the Microbiome Times newsletter